Ladenburg raised the firm’s price target on Rhythm Pharmaceuticals to $43 from $35 and keeps a Buy rating on the shares after Rhythm hosted an R&D event in Boston and presented positive new data from three trials and presentations by the principal investigator of the company’s Phase 2 HO trial. Including risk-adjusted market shares in these DAYBREAK genes led to the firm’s increased price target, the analyst noted.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on RYTM:
- Rhythm announces data from open-label part of Phase 2 DAYBREAK trial
- Rhythm says RM-718 demonstrated potential to reduce body weight, hyperphagia
- Rhythm says setmelanotide demonstrated clinically meaningful reductions in BMI
- Rhythm Pharmaceuticals Announces Updates on MC4R Pathway Programs at R&D Event
- Rhythm Pharmaceuticals Announces New Employment Inducement Grants
